evaluating the effects of coenzyme Q10 in patients with diabetes

evaluating the nephroprotective effects of coenzyme Q10 in patients with diabetic nephropathy : A randomized double blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230212057393N4

Enrollment

Registered

2025-03-09

Start date

2025-03-27

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Intervention group: patient will receive co enzyme Q10 once daily for three month which produced in Darmanyab company. Intervention 2: Control group will receive placebo once daily fo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with type 2 diabetes with ACR above 30. Patients will receive routine albuminuria treatment (losartan).

Exclusion criteria

Exclusion criteria: patients under 18 years Cirrhosis Active neoplasm pregnant patients and Lactating Menopausal women

Design outcomes

Primary

Measure	Time frame
ACR is the urine albumin to creatinine ratio. Timepoint: For the first time at the beginning of study , for second time after three month before medication and after three month of medication will measure again. Method of measurement: Urine albumin to creatinine ratio (ACR).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFahimeh Naderi-Behdani

Mazandaran University of Medical Sciences

fahime.naderi90@gmail.com+98 11 5523 1912

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026